胰岛素抵抗
表观遗传学
小檗碱
生物信息学
2型糖尿病
医学
2型糖尿病
计算生物学
胰岛素
生物
药理学
糖尿病
评论文章
表观遗传学
药物发现
机制(生物学)
疾病
个性化医疗
葡萄糖稳态
代谢组学
糖尿病管理
药品
作者
Da Liu,Liting Zhao,Ying Wang,Lei Wang,Donglu Wu,Yangyang Liu
出处
期刊:Pharmaceuticals
[Multidisciplinary Digital Publishing Institute]
日期:2025-12-14
卷期号:18 (12): 1890-1890
摘要
Type 2 diabetes mellitus (T2DM) is a widespread metabolic disorder characterized by insulin resistance and pancreatic β-cell dysfunction, posing a substantial global health challenge. This review systematically summarizes the therapeutic potential of berberine, a natural isoquinoline alkaloid, in the management of T2DM. Berberine's pharmacological activities are discussed from multiple perspectives, including enhancing insulin sensitivity and regulating glucose metabolism-encompassing glycogen synthesis, gluconeogenesis, and glucose transport. The review also highlights berberine's anti-inflammatory, antioxidant, and epigenetic enzyme-targeting actions and its involvement in key T2DM-related signaling pathways such as AKT, AMPK, and GLUTs. These findings collectively elucidate the multi-targeted and multi-pathway molecular mechanisms underlying berberine's efficacy against T2DM. Additionally, the review covers the pharmacological activities and molecular mechanisms of berberine in treating T2DM complications-including diabetic nephropathy, retinopathy, cardiomyopathy, neuropathy, and diabetic foot ulcers-as well as its clinical and preclinical applications and the synergistic benefits of combination therapy with agents such as metformin, ginsenoside Rb1, and probiotics. By systematically reviewing the literature retrieved from PubMed and Web of Science up to 2025, this article provides a comprehensive summary of current research, offering a theoretical foundation for the clinical use of berberine in T2DM therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI